Cancer drugs and diabetic retinopathy: a dangerous, underestimated association

Abstract

The worldwide growing prevalence of diabetes and cancer led to an increase in subjects affected by both these diseases that share several of the involved risk factors and have a complex, multifactorial etiopathogenesis. Cancer therapies could have harmful effects on several organs, particularly in subjects also affected by diabetes and its related comorbidities. Moreover, cancer diagnosis often monopolizes the attention of both patients and caregivers, thus reducing the attention to pre-existent diseases. Retinopathy is one of the most frequent microvascular complications of diabetes, accounting for about 5% of legal blindness worldwide. The retinal neurovascular unit is dysfunctional in diabetes and could represent a frail site when cancer therapies are administered. Nevertheless, the short- and long-term effects of the different anticancer molecules on retinal tissue, especially in diabetic subjects, are poorly known, and no specific recommendations on their prevention and management are available. In this review, we summarised the current data on this topic, focusing on the different cancer class drugs involved in retinal damage: anti-oestrogen, classical cytolytic chemotherapy (alkylating agents, taxanes, topoisomerase inhibitors, and antimetabolites), mitogen-activated protein kinase, tyrosine-kinase, and vascular endothelial growth factor inhibitors are the cancer drugs associated with retinal damage and visual disturbance. However, further studies are necessary to improve knowledge on the molecular and clinical relation between cancer therapies and retinopathy, in order to provide clinicians with evidence-based protocols to optimise the management of these conditions and minimise vision loss occurrence, impaired quality of life, and public health expense.

Keywords

Diabetes / cancer / retinopathy / blindness / chemotherapy / obesity / chronic complications / hypertension

References

[1] Sun H,Karuranga S.IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res Clin Pract2022;183:109119

[2] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[3] Gallo M,Felicetti F.Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes.Metabolism2018;78:141-54

[4] Milluzzo A,Martorana F,Sciacca L.Type 2 diabetes and cancer: problems and suggestions for best patient management.Explor Med2020;1:184-204.

[5] Giovannucci E,Archer MC.Diabetes and cancer: a consensus report.Diabetes Care2010;33:1674-85 PMCID:PMC2890380

[6] Vella V,Scalisi NM,Sciacca L.Insulin receptor isoforms in cancer.Int J Mol Sci2018;19:3615 PMCID:PMC6274710

[7] Cignarelli A,Caruso I.Diabetes and cancer: pathophysiological fundamentals of a 'dangerous affair'.Diabetes Res Clin Pract2018;143:378-88.

[8] Sciacca L,Cassarino MF.Different effects of the insulin receptor isoforms on 32D cell growth and differentiation.J Diabetes Endocrinol Metab Disord2017;1-9

[9] Pinheiro LC,Kern LM,Safford MM.Diabetes care management patterns before and after a cancer diagnosis: a SEER-Medicare matched cohort study.Cancer2020;126:1727-35

[10] Milluzzo A,Vella V.Short-term adverse effects of anticancer drugs in patients with type 2 diabetes.J Chemother2019;31:150-9.

[11] ElSayed NA,Aroda VR.12. retinopathy, neuropathy, and foot care: standards of care in diabetes-2023.Diabetes Care2023;46:S203-15 PMCID:PMC9810462

[12] Takao T,Yanagisawa H,Iwamoto Y.Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes.Diabetes Res Clin Pract2017;128:15-23

[13] Jampol LM,Sun J.Evaluation and care of patients with diabetic retinopathy.N Engl J Med2020;382:1629-37

[14] Tumminia A,Carrubba N,Baratta R.Excessive generalized and visceral adiposity is associated with a higher prevalence of diabetic retinopathy in Caucasian patients with type 2 diabetes.Nutr Metab Cardiovasc Dis2023;Online ahead of print

[15] Milluzzo A,Maugeri A,Sciacca L.Body mass index is related to short term retinal worsening in type 2 diabetes patients treated with anticancer drugs.Minerva Endocrinol2022;Online ahead of print

[16] Milluzzo A,Barchitta M,Agodi A.Epigenetic mechanisms in type 2 diabetes retinopathy: a systematic review.Int J Mol Sci2021;22:10502. PMCID:PMC8509039

[17] Milluzzo A,Maugeri A.Do nutrients and nutraceuticals play a role in diabetic retinopathy?.Nutrients2022;14:4430 PMCID:PMC9612209

[18] Renouf DJ,Simpson R,Bedard PL.Ocular toxicity of targeted therapies.J Clin Oncol2012;30:3277-86

[19] Liu CY,Brodie SE.Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies.Retina2014;34:1261-80.

[20] Gianni L,Li S.International Breast Cancer Study Group (IBCSG)Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.Cancer2006;106:505-13.

[21] Lamba N.Medication induced retinal side effects.Dis Mon2014;60:263-7

[22] Moussa K,Miller JB.Retinal exudates and hemorrhages in a survivor of breast cancer.JAMA Ophthalmol2019;137:218-9.

[23] Bommireddy T.To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity.BMJ Case Rep2016;2016:bcr2015213431 PMCID:PMC4716368

[24] Bradley MC,Freedman AN.Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer.Cancer Causes Control2018;29:785-91 PMCID:PMC6660131

[25] Derweesh IH,Kincade MC.Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer.BJU Int2007;100:1060-5

[26] Keating NL,O'Malley AJ,Smith MR.Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.Eur Urol2014;65:816-24 PMCID:PMC3779484

[27] Hershey DS,Olausson J,Brady VJ.Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: a review of the literature.Oncol Nurs Forum2014;41:E343-54

[28] Matsuyama K,Wada M,Nishimura T.Case of ischemic retinopathy induced by chemotherapy with paclitaxel and carboplatin.Acta Ophthalmol2008;86:0-0

[29] Elhusseiny AM.Carboplatin- and/or paclitaxel-induced ischemic retinopathy.Can J Ophthalmol2020;55:e95-8

[30] Bassi E,Furino C.Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report.Mol Clin Oncol2017;7:285-7 PMCID:PMC5532694

[31] Chelala E,Antoun J.Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients.Chemotherapy2017;62:199-204

[32] Hilliard LM,Watterson J,Balzer GK.Retinal toxicity associated with cisplatin and etoposide in pediatric patients.Med Pediatr Oncol1997;28:310-3

[33] Kwan AS,Palexes G.Retinal ischemia with neovascularization in cisplatin related retinal toxicity.Am J Ophthalmol2006;141:196-7

[34] Tran THC,Rose C.Gemcitabine-induced retinopathy in a diabetic patient.Acta Ophthalmol2009;87:114-5

[35] Higashide T,Sugiyama K.Cystoid macular edema associated with oral antineoplastic agent s-1 in a patient with diabetic retinopathy.Case Rep Ophthalmol2012;3:91-5 PMCID:PMC3339688

[36] Méndez-Martínez S,Ruiz-Moreno O.Ocular adverse events associated with mek inhibitors.Retina2019;39:1435-50.

[37] AlAli A,Park JC,Lam WC.Pimasertib and serous retinal detachments.Retin Cases Brief Rep2016;10:191-6 PMCID:PMC4890820

[38] Avery RA,Kilburn LB.Separation of outer retinal layers secondary to selumetinib.J AAPOS2016;20:268-71 PMCID:PMC4912405

[39] van Dijk EHC, Kruit WHJ, Jager MJ, Luyten GPM, Vingerling JR, Boon CJF. Pimasertib-associated ophthalmological adverse events.Acta Ophthalmol2018;96:712-8.

[40] van Dijk EH,Marinkovic M.Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (binimetinib) for metastatic cutaneous and uveal melanoma.Ophthalmology2015;122:1907-16.

[41] Watanabe K,Hirashima Y.A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.Cancer Chemother Pharmacol2016;77:1157-64

[42] Rueda-Rueda T,Moruno-Rodríguez A,Martínez-Borrego AC.Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib.Arch Soc Esp Oftalmol2018;93:458-62.

[43] Gulati AP.Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).Anticancer Res2012;32:1375-7

[44] Breccia M,Cannella L.Ocular side effects in chronic myeloid leukemia patients treated with imatinib.Leuk Res2008;32:1022-5.

[45] Kitzmann AS,Mohney BG.Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits.Eye2008;22:712-4

[46] Fraunfelder FT.Oral anti-vascular endothelial growth factor drugs and ocular adverse events.J Ocul Pharmacol Ther2018;34:432-5

[47] Javle M,Kelley RK.Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Lancet Gastroenterol Hepatol2021;6:803-15

[48] Lam WS,Chen FK.A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.Lung Cancer2020;140:87-92

[49] Akturk HK,Sarwal A,Murad MH.Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis.Diabet Med2019;36:1075-81 PMCID:PMC6698212

[50] Dalvin LA,Orloff M,Shields JA.Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects.Retina2018;38:1063-78.

[51] Mantopoulos D,Letson AD.Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma.JAMA Ophthalmol2015;133:965-7 PMCID:PMC4537365

[52] Reddy M,Kalevar A,Agarwal A.Immune retinopathy associated with nivolumab administration for metastatic non-small cell lung cancer.Retin Cases Brief Rep2020;14:120-6

[53] Izumi Y,di Tomaso E,Jain RK.Tumour biology: herceptin acts as an anti-angiogenic cocktail.Nature2002;416:279-80

[54] Saleh M,Noel G,Gaucher D.Bilateral macular ischemia and severe visual loss following trastuzumab therapy.Acta Oncol2011;50:477-8